Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: Orotate phosphoribosyltransferase expression is associated with treatment outcomes

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 991-998

  Choi, In Sil ^b   Lee, Hye Seung ^a   Lee, Keun Wook ^a   Kim, Haeryoung ^a   Kim, Ki Hwan ^a   Kim, Yu Jung ^a   Kim, Jee Hyun ^a   Kim, Woo Ho ^c   Lee, Jong Seok ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Biomarker; Chemotherapy; Cisplatin; Gastric cancer; Orotate phosphoribosyltransferase; S 1

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP D2 PROTEIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUTATHIONE TRANSFERASE P1; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC OR RELAPSED GASTRIC CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84655165068     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9590-4     Document Type: Article

References (29)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
2. U Vanhoefer 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657
3. D Cunningham 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46
4. YK Kang 2009 Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666 673
5. IS Choi 2007 Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer Cancer Res Treat 39 99 103
6. W Koizumi 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212
7. JA Ajani 2006 Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667
8. JL Lee 2008 Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer Cancer Chemother Pharmacol 61 837 845
9. W Koizumi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221
10. N Boku 1998 Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum Clin Cancer Res 4 1469 1474
11. R Metzger 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 309 316
12. S Miyamoto 2000 et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer Int J Oncol 17 653 658
13. W Ichikawa 2004 Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer Br J Cancer 91 1245 1250
14. W Ichikawa 2006 Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1 Int J Cancer 119 1927 1933
15. R Napieralski 2005 Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients Clin Cancer Res 11 3025 3031
16. W Koizumi 2010 Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer Int J Cancer 126 162 170
17. B Liu 2007 Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population Eur J Hum Genet 15 1049 1053
18. KA Olaussen 2006 Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991
19. AD D'Andrea M Grompe 2003 The Fanconi anaemia/BRCA pathway Nat Rev Cancer 3 23 34
20. S Goto 1999 Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells Free Radic Res 31 549 558
21. HS Lee 2001 MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators Cancer 92 1427 1434
22. Choi IS, et al. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol. 2010; doi: 10.1007/s12032-009-9321-x.
23. R Fujii A Seshimo S Kameoka 2003 Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma Int J Clin Oncol 8 72 78
24. Y Kodera 2007 Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil Cancer Lett 252 307 313
25. W Ichikawa 2003 Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer Br J Cancer 89 1486 1492
26. T Shimizu Y Yamada H Yasui K Shirao M Fukuoka 2005 Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine Anticancer Res 25 2997 3001
27. W Koizumi K Saigenji N Nakamaru I Okayasu M Kurihara 1999 Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor Oncology 56 215 222
28. Y Shirota 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 4298 4304
29. HC Kwon 2007 Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Ann Oncol 18 504 509